Sort   by:  
 Page size 
TranscriptomicsHTG EdgeSeq analysis of parental and CDK4/6i-resistant (Ribociclib or Palbociclib) T47D breast cancer cell clones
Do illuminate the vulnerabilities of CDK4/6i-resistant T47D breast cancer cells, we created CDK4/6i-resistant T47D cell clones through a gradual dose escalation protocol using the selective CDK4/6 inhibitors Ribociclib and Palbociclib. We then performed gene expression analysis targeting 2549 genes ...
ORGANISM(S): Homo sapiens 
2026-06-17 | E-MTAB-15265 | biostudies-arrayexpress
UnknownPredictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer.
Not available
S-EPMC11489574 | biostudies-literature
GenomicsCDK4/6i enhances the antitumor effect of PD1 antibody by promoting TLS formation in ovarian cancer
CDK4/6i enhances the antitumor effect of PD1 antibody by promoting TLS formation in ovarian cancer
PRJNA980122 | ENA
GenomicsA genome-wide CRISPRa screening to functionalize lncRNAs in CDK4/6i response [siRNA_RNAseq]
A genome-wide CRISPRa screening to functionalize lncRNAs in CDK4/6i response [siRNA_RNAseq]
PRJNA1175661 | ENA
GenomicsA genome-wide CRISPRa screening to functionalize lncRNAs in CDK4/6i response [activation_RNAseq]
A genome-wide CRISPRa screening to functionalize lncRNAs in CDK4/6i response [activation_RNAseq]
PRJNA1069615 | ENA
GenomicsHTG EdgeSeq analysis of parental and CDK4/6i-resistant (Ribociclib or Palbociclib) T47D breast cancer cell clones
HTG EdgeSeq analysis of parental and CDK4/6i-resistant (Ribociclib or Palbociclib) T47D breast cancer cell clones
PRJEB91038 | ENA
TranscriptomicsCDK4/6i enhances the antitumor effect of PD1 antibody by promoting TLS formation in ovarian cancer
Ovarian cancer is insensitive to immunotherapy and has a high mortality rate. CDK4/6 inhibitors (CDK4/6i) regulate the tumor microenvironment and play an antitumor role. Our previous research demonstrated that lymphocyte aggregation (tertiary lymphoid structures, TLS) was observed after CDK4/6i trea...
ORGANISM(S): Mus musculus 
2023-10-12 | GSE234106 | GEO
GenomicsDownregulation of NSRP1 confers CDK4/6i resistance in breast cancer via activation of the IFN signaling pathway
Downregulation of NSRP1 confers CDK4/6i resistance in breast cancer via activation of the IFN signaling pathway
PRJNA1127666 | ENA
UnknownCombination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
Not available
S-EPMC8979823 | biostudies-literature
UnknownCDK4/6i enhances the antitumor effect of PD1 antibody by promoting TLS formation in ovarian cancer.
Not available
S-EPMC10559077 | biostudies-literature
Sort   by:  
 Page size